Enliven Therapeutics (ELVN) Depreciation & Amortization (CF) (2019 - 2026)

Enliven Therapeutics has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $14000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $14000.0, down 81.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $240000.0 (down 18.92% YoY), and the FY2025 annual result was $300000.0, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) came in at $14000.0 for Q1 2026 at Enliven Therapeutics, down from $83000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $39.0 million in Q1 2022 to a low of $14000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $74000.0 (2023), against an average of $2.4 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 155900.0% in 2022 and slumped 99.83% in 2023, its largest moves.
• Enliven Therapeutics' Depreciation & Amortization (CF) stood at $49000.0 in 2022, then soared by 63.27% to $80000.0 in 2023, then fell by 21.25% to $63000.0 in 2024, then soared by 31.75% to $83000.0 in 2025, then slumped by 83.13% to $14000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $14000.0 (Q1 2026), $83000.0 (Q4 2025), and $62000.0 (Q3 2025), per Business Quant data.